SciCross

[Jury Lab @Jury_Lab]

Just published 📣using #metabolomics and #MachineLearning to identify biomarkers associated with subclinical atherosclerosis in SLE . Great collaboration and tweetorial @inespinedatorra 👇

[SciCross @SciCross]

Really happy to be part of this great collaboration. A deeper understanding of T-cell responses will give insights into protection after Covid-19 infection, as well as what we can expect after vaccination.

#covid19research #SciCross #immunogenicity

https://t.co/NdOOh7IPhc

[SciCross @SciCross]

SciCross is attending CHI’s Immunogenicity & Bioassay Summit 2020 Oct 6-9, presenting collaborative work with Novartis on immunogenicity prediction. #ImmunoBio20 #immunogenicity @Novartis

[SciCross @SciCross]

SciCross is part of the “Biomedical AI-driven data analytics” (BIO-AID) part of this 51 million sek research funding. https://t.co/qqoz33LFP7 (in Swedish only)

[SciCross @SciCross]

New paper! #infliximab #adalimumab #rheumatoidarthritis #ABIRISK #immunogenicity

https://t.co/gcgDwd77jl

[Jury Lab @Jury_Lab]

Early start travelling to #FOCIS 2018 San Francisco. Presenting reduced Notch2 in monocytes predicts anti drug response #MS #ABIRISK

[SciCross @SciCross]

New paper on immunogenicity risk in MS patients treated with Interferon beta published in JCI Insight, https://t.co/4kbBpNK78T. #immunogenicity #MS #ABIRISK

[SciCross @SciCross]

New publication on on protein de-immunization, together with Harvard Medical school and the University of Tubingen.
#immunogenicity #FVIII #computationalimmunology

https://t.co/rpPnPUtO8h

[SciCross @SciCross]

ACR 2017, Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors https://t.co/Rp6JGLd0zB #abirisk

[SciCross @SciCross]

New paper from the ABIRISK consortium. #eTRIKS #MS @IMI_JU
https://t.co/t2gGlCH00R

[SciCross @SciCross]

Not bad! #sweden #innovation These Are the World's Most Innovative Economies https://t.co/wQxC2la0Gz via @markets

[SciCross @SciCross]

New paper from the ABIRISK consortium https://t.co/Ginj1JUuCt #abirisk @IMI_JU #immunogenicity

[SciCross @SciCross]

September issue of the ABIRISK scientific newsletter published http://t.co/Ypg3hb56tg #abirisk #immunogenicity @IMI_JU

[SciCross @SciCross]

Great presenations by #ABIRISK @IMI_JU members on drug #immunogenicity at #ECI2015!

[SciCross @SciCross]

Meet us at the SMi Immunogenicity conference in London, July 14-15, http://t.co/9xVDV8hsJW